Keyphrases
Angiotensin-converting Enzyme Inhibitor (ACEi)
100%
Congestive Heart Failure
98%
Confidence Interval
59%
Hyperkalemia
49%
Danish Population
49%
Potassium Levels
49%
Gene Variants
49%
Risk Factors
49%
Carboxylesterase 1 (CES1)
49%
Population-based Cohort Study
49%
Clinical Outcomes
49%
Occurrence Risk
49%
Chronic Kidney Disease
34%
Spironolactone
30%
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
24%
Urinary Tract Infection
24%
Temporal Regulation
24%
Pharmacogenetics
24%
Pharmacodynamics
24%
Retrospective Cohort Study
24%
Renin-angiotensin-aldosterone System
24%
Prognostic Impact
24%
Calcineurin Inhibitors
24%
Endothelial Function
24%
Angiotensin Receptor Blockers
24%
Randomised Double-blind Clinical Trial
24%
Tubulointerstitial
24%
Ascites
24%
Gas Production
24%
Cerebro
24%
Nephrotoxicity
24%
Potassium
24%
Disease Occurrence
24%
Ruptured Abdominal Aortic Aneurysm (rAAA)
24%
Acute Pyelonephritis
24%
Risk Stratification
24%
Laser Capture Microdissection
24%
All-cause Mortality
24%
Hazard Ratio
23%
Angiotensin II Type 1 Receptor Blocker
22%
Cardiovascular Mortality
20%
Renal Function
18%
Kidney Transplant Recipients
18%
Angiotensin II (Ang II)
18%
Hypertension
17%
Structure-specific
16%
Single nucleotide Polymorphism
16%
Denmark
15%
Pharmacology, Toxicology and Pharmaceutical Science
Dipeptidyl Carboxypeptidase Inhibitor
75%
Congestive Heart Failure
52%
Carboxylesterase
49%
Cohort Study
49%
Chronic Kidney Failure
32%
Spironolactone
27%
Abdominal Aortic Aneurysm
24%
Fibrosis
24%
Nervous System Malformation
24%
Calcineurin Inhibitor
24%
Angiotensin Receptor Antagonist
24%
Hyperkalemia
24%
Lowe Syndrome
24%
Pharmacodynamics
24%
Nephrotoxicity
24%
Nephritis
24%
Isotopes of Potassium
24%
Clinical Trial
24%
Angiotensin 1 Receptor Antagonist
22%
Iron
16%
Medicine and Dentistry
Nephritic Syndrome
24%
Emphysematous Pyelonephritis
24%
Spironolactone
24%
Nephrotoxicity
24%
Calcineurin Inhibitor
24%
Polycystic Kidney Disease
24%
Ascites
24%
Oculocerebrorenal Syndrome
24%
Renin Angiotensin Aldosterone System
24%
Endothelial Function
24%
Clinical Trial
24%
Diseases
24%
Placebo
20%
Biopsy Technique
20%
Supplementation
19%
Fibrosis
18%
Kidney Graft
18%
Gene Expression
16%
